We should be routinely including patients with active brain Mets or LMD in ADC trials starting in phase 1. More and more evidence of a class effect of ADCs in CNS disease and there is a huge unmet medical need.

More (impressive) data on the intracranial activity of T-DXd. Real-world cohort from Japan, including 104 patients with HER2+ MBC, of which 90 with active brain mets and 19 with LMD. Consistently with TUXEDO-1, IC-ORR was 63%, IC-PFS was 16 months. #bcsm nature.com/articles/s4152…

Have a look at our new analysis of impact of quality of life as an endpoint in non-inferiority trials in oncology.
Kudos to Lucrezia Zumstein Jessica Paparo Sara Notarnicola for this work. OncoAlert
ejcancer.com/article/S0959-…
(1/4)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage TNBC academic.oup.com/oncolo/article… There is s lot of good staff that can be learned from a trial non meeting its primary EP. This paper is worthy a full reading 😊😉

Workshop ESMO - Eur. Oncology Cancer Research UK Unicancer after MAP: Toward organ-agnostic, molecular based classifications of cancers. Goal: to define some cancers by their molecular markers, irrespective of organ of origin of the tumor. This will dramatically accelerate drug dvlpt & access

The effect of physical exercise on anticancer immunity | Nature Reviews Immunology nature.com/articles/s4157…

How low can we go with HER2? Can T-DXd improve outcomes for HER2-0 breast cancer? For this Breast Cancer Awareness Month I commit to challenge dogmas & thresholds, with the hope of expanding the benefit of ADCs to more patients in need of novel treatments. aacrjournals.org/cancerdiscover…

Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality nejm.org/doi/full/10.10… This is clear in everyone's mind, but, wow..., the power of these figures...

Extremely honored and grateful for the chance to contribute to this important ASCO research statement on why and how to measure ovarian toxicity in clinical trials: really hope this work can help improving the care of young women with #cancer

OncoAlert

sciencedirect.com/science/articl…

Small (n=40), yet informative randomized phase 2 study testing 2-drugs (gran/dex) vs. 3-drugs (gran/dex/aprepitant) as antiemetic prophylaxis for T-DXd. Adding aprepitant prevented emesis in 70% of the pts, compared with only 36% in the 2-drug regimen arm. jcancer.org/v14p2644.htm

Whenever possible, organ-agnostic, molecular-based classifications are now used at GustaveRoussy . This is a medical & scientific vision shared with many other Institutions, that could dramatically accelerate development and access to innovation. Here HPV 👇

Where Medical Statistics Meets Artificial Intelligence | NEJM nejm.org/doi/full/10.10… Supernice piece from the NEJM!! Worthy of a 'slow reading'😀

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network Very important RCT!!! jamanetwork.com/journals/jamao…

Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models pubmed.ncbi.nlm.nih.gov/37498672/ Very intriguing insights on how stroma may sustain a cancer phenotype be a potential target for combined therapies

Original Research: Oral Health Concerns of Female Breast Cancer Survivors on Adjuvant Endocrine Therapy pubmed.ncbi.nlm.nih.gov/37678330/ Another important health concern to take care of in breast cancer survivors.

A Holy Grail — The Prediction of Protein Structure | NEJM
The 2023 Lasker Award for Basic Medical Research underscores the value of an AI system that predicts the three-dimensional structure of proteins from the one-dimensional sequence of their amino acids.…

First line enfortumab vedotin plus pembro improve PFS and OS over chemotherapy in metastatic urothelial cancer. The ADC era of cancer treatment has just begun.

Nice review of how to manage a very important toxicity for patients with BC. Great resource. ⁦OncoAlert⁩ Physician–Patient Conversations on Sexual Side Effects of Endocrine Therapy in Breast Cancer. ⁦Laila Agrawal, MD⁩ dailynews.ascopubs.org/do/improving-p…

#OpenAccess in Annals of Oncology, results of the ATALANTE-1 RCT investigating OSE2101, a vaccine inducing cytotoxic T lymphocytes against 5 tumor-associated antigens (HER-2, CEA, MAGE 2, MAGE 3 and p53) in HLA-A2+ NSCLC 🫁 after failure of an ICI annalsofoncology.org/article/S0923-… #lcsm

Riunione annuale GIM 2023, premio alle migliori proposte Under40.
Con S. De Placido, M. De Laurentiis, A. Fabi, L. Arecco, F. Poggio, C. Molinelli, A. Rossi, G. Arcuri, L. Gerratana, L. Del Mastro, F. Puglisi.
Luca Arecco, MD Francesca Poggio Lorenzo Gerratana Lucia Del Mastro Fabio Puglisi